leisure time -WSS

leisure time

author：knowledge 2025-08-12 11:30:06 - browse：4

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： AbbVie dramatically boosts its spending on lobbying

WSS

DeSantis can now import cheaper drugs. But will Biden get credit?

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Body of missing toddler recovered in Delaware River days after flood: Police

Our daughter's deadly disease: trisomy 18. We wanted to protect her

JPM 2024: Nvidia claims we're in biological revolution. Are we?

hotspot

leisure time

focus

Virginia high school admissions case could be legal follow

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Hepatitis C has a cure — but many Americans still lack access to it

HIPAA doesn't protect reproductive records from prosecutors

Duchenne breakthrough therapy leaves behind pioneering families

The SUPPORT Act is critical to fighting the opioid crisis

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How artificial intelligence is being used to detect, treat cancer

As demand for Covid shots wanes, Moderna seeks its next success

JPM 2024: Verve Therapeutics looks to mainstream genome editing

leisure time

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

A double vaccine crisis is endangering millions of children

CDC backtracks, saying fully vaccinated people can go maskless indoors

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Heart disease and mental health: A look at cardiac psychology

hotspot

hotspot

hotspot

leisure time